Nasal Drug Delivery Technology Market Size, Trends, Share, Growth | Report 2022-2030
The global nasal drug delivery technology market size was estimated at around USD 71.89 billion in 2022 and it is projected to hit around USD 147.48 billion by 2032, growing at a CAGR of 7.45% from 2023 to 2032.
Key Pointers
The increasing preference of patients for alternative modes of drug administration is one of the major factors expected to fuel the market growth. The growing incidence of chronic disease is expected to affect the overall market growth over the forecast period. According to a study published in Research and Development (RAND) Review blog, a research organization that develops solutions for the public, in 2018, stated that around 60% of American adults had at least one chronic condition, which accounts for hundreds of billions of dollars in healthcare spending every year. In addition, nearly 30 billion Americans live with five chronic conditions or more.
Nasal drug delivery has previously been restricted to topically acting medications used to treat allergies and the common cold. However, there has recently been a rise in interest in nasal delivery as a substitute for oral and intravenous injection for many systemic medications and vaccinations. Highly vascularized and immunogenic nasal mucosa offers prospective benefits including fast action, increased bioavailability, patient compliance, and improved immune response to vaccinations. Moreover, drug administration by using the intranasal route is less invasive, virtually painless, and well-suited for children. The simple, needle-free injection method 0and the permeable application site in the nasal cavity, which allow for a quick start to local and systemic medication effects, are the main benefits. Additionally, trans mucosal nasal absorption protects medicines from hepatic first-pass metabolism and gastrointestinal degradation.
Additionally, influenza (flu) is a very common and highly infectious disease caused by a virus. In 2021, over three billion children were vaccinated against flu across the U.K. This vaccination is carried out by a nasal spray for children. The popular nasal flu vaccines include Fluenz Tetra and FluMist by AstraZeneca AB.
Nasal Drug Delivery Technology Market Segmentations :
| By Dosage Form | By Container Type | By Therapeutic Application | By Distribution Channel |
|
Nasal Spray Nasal Drop Nasal Gel Nasal Powder |
Pressurized Containers Non-pressurized Containers |
Nasal Congestion Rhinitis Asthm Others |
Hospital Pharmacies Retail Pharmacies Online Pharmacies |
Nasal Drug Delivery Technology Market Key Players and Regions Segmentations:
| Key Players | Geography |
|
GlaxoSmithKline PLC AstraZeneca PLC Pfizer, Inc. OptiNose, Inc. Becton, Dickinson and Company Promius Pharma, LLC Cadila Pharmaceuticals Ltd. B.F. Ascher & Company, Inc. PendoPharm, Inc. Douglas Pharmaceuticals Ltd. ENT Technologies Pty. Ltd. NAVEH Pharma Ltd. |
North America Europe Asia-Pacific Latin America Middle East & Africa (MEA) |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nasal Drug Delivery Technology Market
5.1. COVID-19 Landscape: Nasal Drug Delivery Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nasal Drug Delivery Technology Market, By Dosage Form
8.1. Nasal Drug Delivery Technology Market, by Dosage Form, 2023-2032
8.1.1. Nasal Spray
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Nasal Drop
8.1.2.1. Market Revenue and Forecast (2019-2032)
8.1.3. Nasal Gel
8.1.3.1. Market Revenue and Forecast (2019-2032)
8.1.4. Nasal Powder
8.1.4.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Nasal Drug Delivery Technology Market, By Container Type
9.1. Nasal Drug Delivery Technology Market, by Container Type, 2023-2032
9.1.1. Pressurized Containers
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Non-pressurized Containers
9.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Nasal Drug Delivery Technology Market, By Therapeutic Application
10.1. Nasal Drug Delivery Technology Market, by Therapeutic Application, 2023-2032
10.1.1. Nasal Congestion
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Rhinitis
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Asthm
10.1.3.1. Market Revenue and Forecast (2019-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Nasal Drug Delivery Technology Market, By Distribution Channel
11.1. Nasal Drug Delivery Technology Market, by Distribution Channel, 2023-2032
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2019-2032)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2019-2032)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 12. Global Nasal Drug Delivery Technology Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.1.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.1.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.1.5.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.1.6.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.2.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.2.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.2.5.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.2.6.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.2.7.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.2.8.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.3.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.3.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.3.5.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.3.6.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.3.7.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.3.8.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.4.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.4.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.4.5.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.4.6.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.4.7.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.4.8.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.5.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.5.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.5.5.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Dosage Form (2019-2032)
12.5.6.2. Market Revenue and Forecast, by Container Type (2019-2032)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Application (2019-2032)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2019-2032)
Chapter 13. Company Profiles
13.1. GlaxoSmithKline PLC
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca PLC
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. OptiNose, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Becton, Dickinson and Company
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Promius Pharma, LLC
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Cadila Pharmaceuticals Ltd.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. B.F. Ascher & Company, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. PendoPharm, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Douglas Pharmaceuticals Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers